Diabetes drug empagliflozin cuts heart-linked inflammatory cells
A pilot study in Circulation found SGLT2 inhibitor empagliflozin reduced circulating monocyte-platelet aggregates and reprogrammed immune cells away from a.
Simple explainers on world affairs, science, health and more.
All news under one minute
A pilot study in Circulation found SGLT2 inhibitor empagliflozin reduced circulating monocyte-platelet aggregates and reprogrammed immune cells away from a.
A WHO/IARC study in The Lancet Oncology finds about 2.3 million new cancers in 2024 — one in eight — were caused…
Genmab and AbbVie said their epcoritamab plus R-CHOP combination cut the risk of progression or death by 51% in a Phase 3…
Financial Services Secretary Sanjay Lohiya told banks to offer working capital loans via UPI credit lines and the micro-enterprise credit card scheme,…
The 57th GST Council meets October 8 in New Delhi. On the table: removing tax officers' direct arrest powers, raising the prosecution…
Ministry of Steel data shows India's crude steel output hit 85.1 million tonnes in H1 FY27, with finished steel up 3.7% to…
After China suspended fuel exports for October, India — with 23 refineries and 5.6 million bpd capacity — is best placed to…
With 8 states banning analogue paneer and FSSAI's draft rules pending, consumers are shifting to branded dairy. Mother Dairy reports 60-70% demand…
Four Tata trustees accused Venu Srinivasan and Vijay Singh of breaking ranks on keeping Tata Sons unlisted, deepening the dispute over the…
RBI approved Anup Bagchi's appointment as HDFC Bank MD & CEO for three years from October 27, 2026. The ICICI Group veteran…